Russell Investments Group
RLMD icon

Russell Investments Group’s Relmada Therapeutics RLMD Stock Holding History

Russell Investments Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-53
Closed -$159 – 3780
2024
Q2 		$159 Buy
+53
New +$192 ﹤0.01% 3557
2024
Q1 		– Sell
-53
Closed -$219 – 3358
2023
Q4 		$219 Hold
53
– – ﹤0.01% 3176
2023
Q3 		$159 Hold
53
– – ﹤0.01% 3505
2023
Q2 		$130 Sell
53
-60
-53% -$166 ﹤0.01% 3433
2023
Q1 		$255 Buy
+113
New +$390 ﹤0.01% 3254

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Russell Investments Group's RLMD Position: Q3 2024 in Review

Russell Investments Group sold out of Relmada Therapeutics (RLMD) in Q3 2024, closing a stake of 53 shares — an estimated $159 sold.

Russell Investments Group first reported a position in RLMD in Q1 2023 and held it in 5 quarters. The position peaked at $255 in Q1 2023. 69 funds tracked by Wall St. Rank hold RLMD as of Q3 2024.

  • Russell Investments Group reported no remaining Relmada Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Russell Investments Group sold 53 Relmada Therapeutics shares in Q3 2024, an estimated $159.
  • Russell Investments Group first reported a position in Relmada Therapeutics in Q1 2023 and held it in 5 quarters.
  • Russell Investments Group's Relmada Therapeutics position peaked at $255 in Q1 2023.
  • 69 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2024.

Based on Russell Investments Group's 13F filing for Q3 2024, filed 13 Nov 2024.